How Big Will the SpaceX IPO Be?
Operated up to now as a private business, SpaceX will…
Sell
40
CGEN Quote, Financials, Valuation and Earnings
Last price:
$1.98
Seasonality move
:
-2.67%
Day range:
$1.94 - $2.03
52-week range:
$1.13 - $2.66
Dividend yield:
0%
P/E ratio:
55.83x
P/S ratio:
26.05x
P/B ratio:
4.16x
Volume:
291.8K
Avg. volume:
566.2K
1-year change:
-14.85%
Market cap:
$182.4M
Revenue:
$27.9M
EPS (TTM):
-$0.30
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
CGEN
Compugen Ltd.
|
$14.3M | $0.14 | -63.51% | -2.83% | $5.80 |
|
CANF
Can-Fite BioPharma Ltd.
|
-- | -- | -3.23% | -72.97% | $2.50 |
|
KMDA
Kamada Ltd.
|
$45.8M | $0.08 | 6.52% | 59.65% | $13.00 |
|
NSRX
Nasus Pharma
|
-- | -- | -- | -- | -- |
|
PHGE
BiomX, Inc.
|
-- | -$5.06 | -- | -66.65% | $399.00 |
|
TEVA
Teva Pharmaceutical Industries Ltd.
|
$4.3B | $0.64 | 3.18% | 223.87% | $35.59 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
CGEN
Compugen Ltd.
|
$1.95 | $5.80 | $182.4M | 55.83x | $0.00 | 0% | 26.05x |
|
CANF
Can-Fite BioPharma Ltd.
|
$4.43 | $2.50 | $3.8M | -- | $0.00 | 0% | 24.71x |
|
KMDA
Kamada Ltd.
|
$8.64 | $13.00 | $498.4M | 24.32x | $0.20 | 0% | 2.84x |
|
NSRX
Nasus Pharma
|
-- | -- | -- | -- | $0.00 | 0% | -- |
|
PHGE
BiomX, Inc.
|
$6.58 | $399.00 | $10M | -- | $0.00 | 0% | -- |
|
TEVA
Teva Pharmaceutical Industries Ltd.
|
$33.21 | $35.59 | $38.1B | 27.25x | $0.00 | 0% | 2.22x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
CGEN
Compugen Ltd.
|
6.3% | 3.013 | 2.14% | 4.24x |
|
CANF
Can-Fite BioPharma Ltd.
|
-- | 0.913 | -- | -- |
|
KMDA
Kamada Ltd.
|
4.15% | 0.784 | 2.87% | 2.16x |
|
NSRX
Nasus Pharma
|
-- | 0.000 | -- | -- |
|
PHGE
BiomX, Inc.
|
38.57% | 1.023 | 20.14% | 1.51x |
|
TEVA
Teva Pharmaceutical Industries Ltd.
|
68.37% | 0.421 | 47.73% | 0.55x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
CGEN
Compugen Ltd.
|
$241K | -$7.9M | -49.12% | -51.8% | -417.4% | -- |
|
CANF
Can-Fite BioPharma Ltd.
|
-- | -- | -- | -- | -- | -- |
|
KMDA
Kamada Ltd.
|
$19.8M | $7.8M | 7.58% | 7.91% | 16.6% | $7.3M |
|
NSRX
Nasus Pharma
|
-- | -- | -- | -- | -- | -- |
|
PHGE
BiomX, Inc.
|
-$1.2M | -$8.5M | -116.24% | -160.84% | -- | -$7.2M |
|
TEVA
Teva Pharmaceutical Industries Ltd.
|
$2.7B | $1.3B | 5.91% | 20.99% | 26.92% | $1.3B |
Compugen Ltd. vs. Competitors
-
Which has Higher Returns CGEN or CANF?
Can-Fite BioPharma Ltd. has a net margin of -369.06% compared to Compugen Ltd.'s net margin of --. Compugen Ltd.'s return on equity of -51.8% beat Can-Fite BioPharma Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CGENCompugen Ltd.12.75% -$0.07 $46.8M CANFCan-Fite BioPharma Ltd.-- -- -- -
What do Analysts Say About CGEN or CANF?
Compugen Ltd. has a consensus price target of $5.80, signalling upside risk potential of 197.44%. On the other hand Can-Fite BioPharma Ltd. has an analysts' consensus of $2.50 which suggests that it could grow by 1028.67%. Given that Can-Fite BioPharma Ltd. has higher upside potential than Compugen Ltd., analysts believe Can-Fite BioPharma Ltd. is more attractive than Compugen Ltd..
Company Buy Ratings Hold Ratings Sell Ratings CGENCompugen Ltd.5 0 0 CANFCan-Fite BioPharma Ltd.1 1 0 -
Is CGEN or CANF More Risky?
Compugen Ltd. has a beta of 2.847, which suggesting that the stock is 184.728% more volatile than S&P 500. In comparison Can-Fite BioPharma Ltd. has a beta of 1.029, suggesting its more volatile than the S&P 500 by 2.931%.
-
Which is a Better Dividend Stock CGEN or CANF?
Compugen Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Can-Fite BioPharma Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Compugen Ltd. pays -- of its earnings as a dividend. Can-Fite BioPharma Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CGEN or CANF?
Compugen Ltd. quarterly revenues are $1.9M, which are larger than Can-Fite BioPharma Ltd. quarterly revenues of --. Compugen Ltd.'s net income of -$7M is higher than Can-Fite BioPharma Ltd.'s net income of --. Notably, Compugen Ltd.'s price-to-earnings ratio is 55.83x while Can-Fite BioPharma Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Compugen Ltd. is 26.05x versus 24.71x for Can-Fite BioPharma Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CGENCompugen Ltd.26.05x 55.83x $1.9M -$7M CANFCan-Fite BioPharma Ltd.24.71x -- -- --
-
Which has Higher Returns CGEN or KMDA?
Kamada Ltd. has a net margin of -369.06% compared to Compugen Ltd.'s net margin of 11.27%. Compugen Ltd.'s return on equity of -51.8% beat Kamada Ltd.'s return on equity of 7.91%.
Company Gross Margin Earnings Per Share Invested Capital CGENCompugen Ltd.12.75% -$0.07 $46.8M KMDAKamada Ltd.42.04% $0.09 $276.7M -
What do Analysts Say About CGEN or KMDA?
Compugen Ltd. has a consensus price target of $5.80, signalling upside risk potential of 197.44%. On the other hand Kamada Ltd. has an analysts' consensus of $13.00 which suggests that it could grow by 50.46%. Given that Compugen Ltd. has higher upside potential than Kamada Ltd., analysts believe Compugen Ltd. is more attractive than Kamada Ltd..
Company Buy Ratings Hold Ratings Sell Ratings CGENCompugen Ltd.5 0 0 KMDAKamada Ltd.3 0 0 -
Is CGEN or KMDA More Risky?
Compugen Ltd. has a beta of 2.847, which suggesting that the stock is 184.728% more volatile than S&P 500. In comparison Kamada Ltd. has a beta of 0.927, suggesting its less volatile than the S&P 500 by 7.303%.
-
Which is a Better Dividend Stock CGEN or KMDA?
Compugen Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Kamada Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.20 per share. Compugen Ltd. pays -- of its earnings as a dividend. Kamada Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CGEN or KMDA?
Compugen Ltd. quarterly revenues are $1.9M, which are smaller than Kamada Ltd. quarterly revenues of $47M. Compugen Ltd.'s net income of -$7M is lower than Kamada Ltd.'s net income of $5.3M. Notably, Compugen Ltd.'s price-to-earnings ratio is 55.83x while Kamada Ltd.'s PE ratio is 24.32x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Compugen Ltd. is 26.05x versus 2.84x for Kamada Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CGENCompugen Ltd.26.05x 55.83x $1.9M -$7M KMDAKamada Ltd.2.84x 24.32x $47M $5.3M
-
Which has Higher Returns CGEN or NSRX?
Nasus Pharma has a net margin of -369.06% compared to Compugen Ltd.'s net margin of --. Compugen Ltd.'s return on equity of -51.8% beat Nasus Pharma's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CGENCompugen Ltd.12.75% -$0.07 $46.8M NSRXNasus Pharma-- -- -- -
What do Analysts Say About CGEN or NSRX?
Compugen Ltd. has a consensus price target of $5.80, signalling upside risk potential of 197.44%. On the other hand Nasus Pharma has an analysts' consensus of -- which suggests that it could fall by --. Given that Compugen Ltd. has higher upside potential than Nasus Pharma, analysts believe Compugen Ltd. is more attractive than Nasus Pharma.
Company Buy Ratings Hold Ratings Sell Ratings CGENCompugen Ltd.5 0 0 NSRXNasus Pharma0 0 0 -
Is CGEN or NSRX More Risky?
Compugen Ltd. has a beta of 2.847, which suggesting that the stock is 184.728% more volatile than S&P 500. In comparison Nasus Pharma has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock CGEN or NSRX?
Compugen Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nasus Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Compugen Ltd. pays -- of its earnings as a dividend. Nasus Pharma pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CGEN or NSRX?
Compugen Ltd. quarterly revenues are $1.9M, which are larger than Nasus Pharma quarterly revenues of --. Compugen Ltd.'s net income of -$7M is higher than Nasus Pharma's net income of --. Notably, Compugen Ltd.'s price-to-earnings ratio is 55.83x while Nasus Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Compugen Ltd. is 26.05x versus -- for Nasus Pharma. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CGENCompugen Ltd.26.05x 55.83x $1.9M -$7M NSRXNasus Pharma-- -- -- --
-
Which has Higher Returns CGEN or PHGE?
BiomX, Inc. has a net margin of -369.06% compared to Compugen Ltd.'s net margin of --. Compugen Ltd.'s return on equity of -51.8% beat BiomX, Inc.'s return on equity of -160.84%.
Company Gross Margin Earnings Per Share Invested Capital CGENCompugen Ltd.12.75% -$0.07 $46.8M PHGEBiomX, Inc.-- -$5.55 $17.1M -
What do Analysts Say About CGEN or PHGE?
Compugen Ltd. has a consensus price target of $5.80, signalling upside risk potential of 197.44%. On the other hand BiomX, Inc. has an analysts' consensus of $399.00 which suggests that it could grow by 2407.6%. Given that BiomX, Inc. has higher upside potential than Compugen Ltd., analysts believe BiomX, Inc. is more attractive than Compugen Ltd..
Company Buy Ratings Hold Ratings Sell Ratings CGENCompugen Ltd.5 0 0 PHGEBiomX, Inc.1 0 0 -
Is CGEN or PHGE More Risky?
Compugen Ltd. has a beta of 2.847, which suggesting that the stock is 184.728% more volatile than S&P 500. In comparison BiomX, Inc. has a beta of 1.599, suggesting its more volatile than the S&P 500 by 59.937%.
-
Which is a Better Dividend Stock CGEN or PHGE?
Compugen Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BiomX, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Compugen Ltd. pays -- of its earnings as a dividend. BiomX, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CGEN or PHGE?
Compugen Ltd. quarterly revenues are $1.9M, which are larger than BiomX, Inc. quarterly revenues of --. Compugen Ltd.'s net income of -$7M is higher than BiomX, Inc.'s net income of -$9.2M. Notably, Compugen Ltd.'s price-to-earnings ratio is 55.83x while BiomX, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Compugen Ltd. is 26.05x versus -- for BiomX, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CGENCompugen Ltd.26.05x 55.83x $1.9M -$7M PHGEBiomX, Inc.-- -- -- -$9.2M
-
Which has Higher Returns CGEN or TEVA?
Teva Pharmaceutical Industries Ltd. has a net margin of -369.06% compared to Compugen Ltd.'s net margin of 10.19%. Compugen Ltd.'s return on equity of -51.8% beat Teva Pharmaceutical Industries Ltd.'s return on equity of 20.99%.
Company Gross Margin Earnings Per Share Invested Capital CGENCompugen Ltd.12.75% -$0.07 $46.8M TEVATeva Pharmaceutical Industries Ltd.56.15% $0.41 $25B -
What do Analysts Say About CGEN or TEVA?
Compugen Ltd. has a consensus price target of $5.80, signalling upside risk potential of 197.44%. On the other hand Teva Pharmaceutical Industries Ltd. has an analysts' consensus of $35.59 which suggests that it could grow by 6.35%. Given that Compugen Ltd. has higher upside potential than Teva Pharmaceutical Industries Ltd., analysts believe Compugen Ltd. is more attractive than Teva Pharmaceutical Industries Ltd..
Company Buy Ratings Hold Ratings Sell Ratings CGENCompugen Ltd.5 0 0 TEVATeva Pharmaceutical Industries Ltd.8 0 0 -
Is CGEN or TEVA More Risky?
Compugen Ltd. has a beta of 2.847, which suggesting that the stock is 184.728% more volatile than S&P 500. In comparison Teva Pharmaceutical Industries Ltd. has a beta of 0.659, suggesting its less volatile than the S&P 500 by 34.132%.
-
Which is a Better Dividend Stock CGEN or TEVA?
Compugen Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Teva Pharmaceutical Industries Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Compugen Ltd. pays -- of its earnings as a dividend. Teva Pharmaceutical Industries Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CGEN or TEVA?
Compugen Ltd. quarterly revenues are $1.9M, which are smaller than Teva Pharmaceutical Industries Ltd. quarterly revenues of $4.7B. Compugen Ltd.'s net income of -$7M is lower than Teva Pharmaceutical Industries Ltd.'s net income of $483M. Notably, Compugen Ltd.'s price-to-earnings ratio is 55.83x while Teva Pharmaceutical Industries Ltd.'s PE ratio is 27.25x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Compugen Ltd. is 26.05x versus 2.22x for Teva Pharmaceutical Industries Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CGENCompugen Ltd.26.05x 55.83x $1.9M -$7M TEVATeva Pharmaceutical Industries Ltd.2.22x 27.25x $4.7B $483M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will ISRG Stock Be in 5 Years?
Intuitive Surgical (NASDAQ:ISRG) is the innovative medical tech business behind…
Is Kratos Stock a Good Investment?
UAV and hypersonic system defense contractor Kratos (NASDAQ:KTOS) has swung…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.7T
P/E Ratio: 65x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Sell
48
Is GOOGL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Alerts
Sell
48
SANM alert for Jan 29
Sanmina Corp. [SANM] is up 6.61% over the past day.
Buy
72
BNAI alert for Jan 29
Brand Engagement Network, Inc. [BNAI] is up 20.87% over the past day.
Buy
58
AAOI alert for Jan 29
Applied Optoelectronics, Inc. [AAOI] is up 20.97% over the past day.
